ALLO
Allogene Therapeutics, Inc. · Healthcare · Market cap $459.5M
Insiders sold $63K net in the last 90 days ·1 seller, 0 buyers· latest Form 4 filed Aug 25, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$666K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Aug 25, 2026
Douglas Earl Martin
Allogene Therapeutics, Inc. (ALLO) has 17 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 25, 2026.
Inside the rolling window, 6 insiders at Allogene Therapeutics, Inc. reported no open-market purchases and 15 open-market sales totaling $666K. The most active filer is SVP, Chief Technical Officer Beneski Benjamin Machinas with 5 filings. Insiders have net sold $241K over the trailing 6 months. The most recent open-market filing is a sale of 29,697 shares by SVP, General Counsel Douglas Earl Martin, dated Aug 21, 2026, worth $63K.
- Industry:Biotechnology
- CEO:Zachary Roberts
- Employees:151
- HQ:South San Francisco, CA, US
- IPO:2018-10-11
| Source | |||||||
|---|---|---|---|---|---|---|---|
Douglas Earl MartinFirst in 7 months | SVP, General Counsel | Sale | 29,697 | $63K | Aug 25 | -38.7% | SEC ↗ |
| SVP, Finance | Sale | 9,586 | $22K | Apr 23 | -43.4% | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 2,867 | $7K | Apr 2 | -46.4% | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 4,835 | $12K | Mar 18 | -38.1% | SEC ↗ | |
| President and CEO | Sale | 47,763 | $118K | Mar 18 | -38.1% | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 7,132 | $19K | Mar 4 | -47.4% | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 7,549 | $13K | Feb 4 | -26.1% | SEC ↗ | |
Yoshiyama AnnieFirst filing | SVP, Finance | Sale | 4,167 | $7K | Feb 4 | -26.1% | SEC ↗ |
| EVP of R&D | Sale | 35,700 | $63K | Feb 4 | -26.1% | SEC ↗ | |
Douglas Earl MartinFirst filing | SVP, General Counsel | Sale | 22,900 | $40K | Feb 4 | -26.1% | SEC ↗ |
| CHIEF FINANCIAL OFFICER | Sale | 24,001 | $42K | Feb 4 | — | SEC ↗ | |
Chang David DFirst filing | President and CEO | Sale | 95,269 | $171K | Feb 4 | — | SEC ↗ |
Roberts ZacharyFirst filing | EVP of R&D | Sale | 26,269 | $41K | Jan 23 | — | SEC ↗ |
Beneski Benjamin MachinasFirst filing | SVP, Chief Technical Officer | Sale | 786 | $959 | Nov 19 | — | SEC ↗ |
Parker Geoffrey M.First filing | CHIEF FINANCIAL OFFICER | Sale | 36,744 | $46K | Oct 23 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does ALLO have?
Allogene Therapeutics, Inc. (ALLO) has 17 SEC Form 4 filings (17 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Aug 25, 2026.
When was the most recent SEC Form 4 filing for ALLO?
The most recent Form 4 filing for ALLO on Tracefour is dated Aug 25, 2026.
Who is the most active insider at ALLO?
The most active SEC Form 4 filer at ALLO in the rolling window is SVP, Chief Technical Officer Beneski Benjamin Machinas, with 5 filings.
What is the net insider flow at ALLO over the last 6 months?
Over the trailing 180 days, insiders at ALLO have net sold $241K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ALLO in the current window?
Inside the rolling window, insiders at ALLO bought $0 and sold $666K based on SEC Form 4 filings.
Can I get alerts for ALLO insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Allogene Therapeutics, Inc. (ALLO). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Allogene Therapeutics, Inc. is in the Healthcare sector.